MA51795A - Oligonucléotides pour moduler l'expression de tmem106b - Google Patents

Oligonucléotides pour moduler l'expression de tmem106b

Info

Publication number
MA51795A
MA51795A MA051795A MA51795A MA51795A MA 51795 A MA51795 A MA 51795A MA 051795 A MA051795 A MA 051795A MA 51795 A MA51795 A MA 51795A MA 51795 A MA51795 A MA 51795A
Authority
MA
Morocco
Prior art keywords
tmem106b
oligonucleotides
modulate
expression
Prior art date
Application number
MA051795A
Other languages
English (en)
Inventor
Benny Chih
Amy Easton
Peter Hagedorn
Marianne L Jensen
Lukasz Kielpinski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA51795A publication Critical patent/MA51795A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA051795A 2018-02-09 2019-02-08 Oligonucléotides pour moduler l'expression de tmem106b MA51795A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18156142 2018-02-09
US201862669251P 2018-05-09 2018-05-09

Publications (1)

Publication Number Publication Date
MA51795A true MA51795A (fr) 2020-12-16

Family

ID=65433647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051795A MA51795A (fr) 2018-02-09 2019-02-08 Oligonucléotides pour moduler l'expression de tmem106b

Country Status (17)

Country Link
US (1) US11485975B2 (fr)
EP (1) EP3749766A1 (fr)
JP (1) JP7281474B2 (fr)
KR (1) KR20200108315A (fr)
CN (1) CN111868245B (fr)
AU (1) AU2019219194A1 (fr)
BR (1) BR112020016170A2 (fr)
CA (1) CA3088071A1 (fr)
CL (1) CL2020002038A1 (fr)
CR (1) CR20200346A (fr)
IL (1) IL276357A (fr)
MA (1) MA51795A (fr)
MX (1) MX2020008290A (fr)
PE (1) PE20211197A1 (fr)
RU (1) RU2020125769A (fr)
SG (1) SG11202007093YA (fr)
WO (1) WO2019154979A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058152A4 (fr) * 2019-11-14 2024-05-08 The Board of Regents of the University of Oklahoma Traitements du cancer de la prostate par interférence d'oligonucléotides
CN115551519A (zh) * 2020-05-11 2022-12-30 基因泰克公司 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
CN119095963A (zh) 2022-01-10 2024-12-06 杭州浩博医药有限公司 乙型肝炎病毒(hbv)表达的调节
WO2023141507A1 (fr) * 2022-01-20 2023-07-27 Genentech, Inc. Oligonucléotides antisens pour moduler l'expression de tmem106b
TW202440925A (zh) * 2023-01-10 2024-10-16 美商浩博生物醫藥有限公司 供使用之經修飾之多段式反義寡核苷酸

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2303299C (fr) 1997-09-12 2016-02-23 Exiqon A/S Analogues d'oligonucleotides
PT1152009E (pt) 1999-02-12 2005-03-31 Sankyo Co Novos analogos de nucleosidos e oligonucleotidos
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
AU2002303176A1 (en) 2001-03-27 2002-10-15 University Of Delaware Genomics applications for modified oligonucleotides
ES2609014T3 (es) 2001-07-12 2017-04-18 University Of Massachusetts Producción in vivo de ARN de interferencia pequeños que median el silenciamiento génico
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US9045518B2 (en) 2002-11-18 2015-06-02 Santaris Pharma A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
US8653252B2 (en) 2003-03-21 2014-02-18 Santaris Pharma A/S Short interfering RNA (siRNA) analogues
EP1752536A4 (fr) * 2004-05-11 2008-04-16 Alphagen Co Ltd Polynucleotide provoquant l'interference rna et procede de regulation d'expression genetique avec l'usage de ce dernier
WO2006034348A2 (fr) 2004-09-17 2006-03-30 Isis Pharmaceuticals, Inc. Oligonucleotides antisens ameliores
WO2007031091A2 (fr) 2005-09-15 2007-03-22 Santaris Pharma A/S Composes antagonistes d'arn de modulation de l'expression de p21 ras
ES2351674T3 (es) 2006-01-27 2011-02-09 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
AU2007229161B2 (en) 2006-03-23 2012-07-12 Roche Innovation Center Copenhagen A/S Small internally segmented interfering RNA
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
CA2651453C (fr) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. Analogues d'acides nucleiques bicycliques modifies en 5'
CA2667055C (fr) 2006-10-18 2017-05-09 Isis Pharmaceuticals, Inc. Composes antisens
EP2170917B1 (fr) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué
EP2173760B2 (fr) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique bicyclique carbocylique
EP2176280B2 (fr) 2007-07-05 2015-06-24 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques disubstitués en position 6
WO2009067647A1 (fr) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique alpha-l-bicyclique carbocyclique
US8501805B2 (en) 2008-09-24 2013-08-06 Isis Pharmaceuticals, Inc. Substituted alpha-L-bicyclic nucleosides
EP2379083B1 (fr) 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Agents allongés servant de substrats de dicer et procédés d'inhibition spécifique de l'expression d'un gène
WO2010093788A2 (fr) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Molécules d'arn interférence substrats de dicer multiplexes ayant des séquences de jonction
JP5879256B2 (ja) 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011156202A1 (fr) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. 2'‑amino- et 2'‑thio-nucléosides bicycliques substitués et composés oligomères préparés à partir de ces derniers
AU2011263642B2 (en) 2010-06-11 2014-09-04 Isarna Therapeutics Gmbh Method for selective oligonucleotide modification
AU2011325956B2 (en) * 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP3067421B1 (fr) 2011-02-08 2018-10-10 Ionis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations
JP2014514313A (ja) 2011-04-20 2014-06-19 ロシュ グリクアート アクチェンゲゼルシャフト 血液脳関門のｐＨ依存性通過のための方法及び構築物
US10202599B2 (en) 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP2850092B1 (fr) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Analogues tricycliques d'acide nucléique
SG11201407486PA (en) * 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression
WO2013173647A1 (fr) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions et méthodes pour moduler l'expression de apoa1 et de abca1
WO2013173637A1 (fr) * 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions et méthodes pour moduler l'expression génique
SG10201804331TA (en) * 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
JP2017505623A (ja) 2014-01-30 2017-02-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 生物切断性コンジュゲートを有するポリオリゴマー化合物
US20150231151A1 (en) 2014-02-19 2015-08-20 University Of Houston System Compositions and methods for the treatment of neurodegenerative diseases
CN104450621B (zh) * 2014-09-30 2018-10-19 首都医科大学附属北京口腔医院 Wdr63基因在间充质干细胞骨向和牙向分化过程中的调控方法
EP3253871A1 (fr) * 2015-02-04 2017-12-13 Bristol-Myers Squibb Company Oligonucléotides lna à flancs alternés
SG11201706293XA (en) * 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof

Also Published As

Publication number Publication date
US20210054383A1 (en) 2021-02-25
CN111868245B (zh) 2024-11-19
WO2019154979A1 (fr) 2019-08-15
IL276357A (en) 2020-09-30
BR112020016170A2 (pt) 2020-12-15
EP3749766A1 (fr) 2020-12-16
CR20200346A (es) 2020-10-19
US11485975B2 (en) 2022-11-01
JP2021514182A (ja) 2021-06-10
CL2020002038A1 (es) 2020-10-23
RU2020125769A3 (fr) 2022-03-10
JP7281474B2 (ja) 2023-05-25
AU2019219194A1 (en) 2020-08-06
CN111868245A (zh) 2020-10-30
SG11202007093YA (en) 2020-08-28
PE20211197A1 (es) 2021-07-01
KR20200108315A (ko) 2020-09-17
MX2020008290A (es) 2020-09-25
CA3088071A1 (fr) 2019-08-15
RU2020125769A (ru) 2022-03-10

Similar Documents

Publication Publication Date Title
EP3768854A4 (fr) Modulation de l'expression de hsd17b13
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3724780A4 (fr) Évolution d'architectures pour réseaux neuronaux multitâches
EP3607023C0 (fr) Solutions micellaires pour traitement de formations d'hydrocarbures
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
EP3853365A4 (fr) Modulateurs de l'expression de pnpla3
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3442488A4 (fr) Compositions pour l'application topique de composés
EP3431075A4 (fr) Forme galénique d'édaravone
EP3692028A4 (fr) Inhibition de la peptidase 30 spécifique de l'ubiquitine
EP3359164A4 (fr) Composés et procédés pour moduler l'expression de l'angiotensinogène
MA53924A (fr) Modulateurs de l'expression d'apol1
EP3700516A4 (fr) Inhibiteurs de l'induction de dux4 pour la régulation de la fonction musculaire
EP3645039A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
EP3645040A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
EP3476478A4 (fr) Composition pour l'élimination de composés soufrés
EP3723768A4 (fr) Composés pour le traitement et la prévention de pathologies médiées par l'histone extracellulaire
EP3634426A4 (fr) Compositions pour le traitement d'une fibrose
EP3397288A4 (fr) Méthodes pour diminuer l'expression de l'ataxine-2
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
MA51645A (fr) Modulateurs de l'expression de dnm2
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
MA51738A (fr) Composés pour le traitement de la douleur